Literature DB >> 30468306

A rapid method for estimation of the efficacy of potential antimicrobials in humans and animals by agar diffusion assay.

Elena G Salina1, Sean Ekins2, Vadim A Makarov1.   

Abstract

Drug resistance continues to challenge traditional antimicrobial drugs and limit their clinical utility. This requires us to continue our search for new drug candidates with novel mechanisms of action against infectious diseases. We now describe a simple agar diffusion assay, which can be used as a general method for the rapid detection of antimicrobial activity of drug candidates in animal or human blood plasma for the ultimate prediction of the efficacy of potential drugs prior to clinical trials. We present an example for a clinical candidate against Mycobacterium tuberculosis.
© 2018 John Wiley & Sons A/S.

Entities:  

Keywords:  Tuberculosis; agar diffusion assay; antimicrobial activity; clinical trials; drug candidate; macozinone

Mesh：

Substances：

Year:  2018        PMID： 30468306      PMCID： PMC6533168          DOI： 10.1111/cbdd.13427

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN： 1747-0277            Impact factor:   2.817


  19 in total

1.  Mycobacterium smegmatis and tuberculosis.

Authors:  Jaya Sivaswami Tyagi; Deepak Sharma
Journal:  Trends Microbiol       Date:  2002-02       Impact factor: 17.079

2.  Mycobacterium smegmatis: an absurd model for tuberculosis?

Authors:  J M Reyrat; D Kahn
Journal:  Trends Microbiol       Date:  2001-10       Impact factor: 17.079

3.  The perpetual challenge of infectious diseases.

Authors:  Anthony S Fauci; David M Morens
Journal:  N Engl J Med       Date:  2012-02-02       Impact factor: 91.245

Review 4.  The magic bullets and tuberculosis drug targets.

Authors:  Ying Zhang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

Review 5.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

6.  Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.

Authors:  Mudassar Altaf; Christopher H Miller; David S Bellows; Ronan O'Toole
Journal:  Tuberculosis (Edinb)       Date:  2010-10-12       Impact factor: 3.131

7.  Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.

Authors:  Vadim Makarov; Giulia Manina; Katarina Mikusova; Ute Möllmann; Olga Ryabova; Brigitte Saint-Joanis; Neeraj Dhar; Maria Rosalia Pasca; Silvia Buroni; Anna Paola Lucarelli; Anna Milano; Edda De Rossi; Martina Belanova; Adela Bobovska; Petronela Dianiskova; Jana Kordulakova; Claudia Sala; Elizabeth Fullam; Patricia Schneider; John D McKinney; Priscille Brodin; Thierry Christophe; Simon Waddell; Philip Butcher; Jakob Albrethsen; Ida Rosenkrands; Roland Brosch; Vrinda Nandi; Sowmya Bharath; Sheshagiri Gaonkar; Radha K Shandil; Venkataraman Balasubramanian; Tanjore Balganesh; Sandeep Tyagi; Jacques Grosset; Giovanna Riccardi; Stewart T Cole
Journal:  Science       Date:  2009-03-19       Impact factor: 47.728

Review 8.  DprE1--from the discovery to the promising tuberculosis drug target.

Authors:  Katarína Mikusová; Vadim Makarov; João Neres
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 9.  New small-molecule synthetic antimycobacterials.

Authors:  Lluis Ballell; Robert A Field; Ken Duncan; Robert J Young
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

10.  Towards a new combination therapy for tuberculosis with next generation benzothiazinones.

Authors:  Vadim Makarov; Benoit Lechartier; Ming Zhang; João Neres; Astrid M van der Sar; Susanne A Raadsen; Ruben C Hartkoorn; Olga B Ryabova; Anthony Vocat; Laurent A Decosterd; Nicolas Widmer; Thierry Buclin; Wilbert Bitter; Koen Andries; Florence Pojer; Paul J Dyson; Stewart T Cole
Journal:  EMBO Mol Med       Date:  2014-02-05       Impact factor: 12.137
View more
  1 in total

1.  Drug Delivery from PCL/Chitosan Multilayer Coatings for Metallic Implants.

Authors:  Íris Soares; Jaime Faria; Ana Marques; Isabel A C Ribeiro; Carlos Baleizão; Ana Bettencourt; Isabel M M Ferreira; Ana Catarina Baptista
Journal:  ACS Omega       Date:  2022-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.